Core Viewpoint - The company, Nuo Cheng Jian Hua, experienced a stock decline of over 4% following the release of its interim financial results, despite reporting significant revenue growth and reduced losses [1]. Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 731 million, representing a year-on-year increase of 74.26% [1]. - The adjusted loss for the period was RMB 15.5 million, a decrease of 93.62% compared to the previous year [1]. - The loss attributable to the parent company was RMB 30.1 million, down 88.51% year-on-year [1]. - The earnings per share were reported at a loss of RMB 0.02 [1]. Revenue Drivers - The increase in revenue was primarily driven by strong sales of Obutuzumab and licensing income from Prolium [1]. - Revenue from Obutuzumab rose from RMB 417 million for the six months ending June 30, 2024, to RMB 637 million for the same period in 2025, marking a growth of 52.8% due to an expanded coverage and an increase in treated patients [1].
港股异动 | 诺诚健华(09969)绩后跌超4% 上半年母公司拥有人应占亏损3009.1万元 同比收窄88.51%